Resources

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

A new formulation of Insulin Aspart can offer better glycemic control and may also be given after meals.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Among long-term users, discontinuation of low-dose aspirin in absence of surgery or bleeding had a greater than 30% increased risk of cardiovascular events.

When recommending an insulin pen to a patient, do you have sample pens to demonstrate how to use properly? Follow the link to see how you compare to your colleagues.

Your 42-year-old, overweight patient was diagnosed with type 2 diabetes (A1C 7.7%) five months ago. You discussed the diagnosis with him, prescribed metformin, and provided lifestyle modification education resources. He missed his follow-up appointment, so you called him to schedule a return visit. At this appointment, he shares some of the positive lifestyle modifications he has made and that he has been taking his metformin consistently. He currently takes 2,000 mg metformin per day. At this visit, his A1C is 9.4%. All of the following are reasonable treatment options EXCEPT: A. Metformin+ lifestyle modifications B. Metformin + once-daily evening basal insulin dose + lifestyle modifications C. Metformin + sulfonylurea+ lifestyle modifications D. Metformin + GLP-1 receptor agonist + lifestyle modifications Follow the link to see the correct answer.

R. Keith Campbell, RPh, MBA, CDE, FASHP, FAPhA, FAADE, is the former Associate Dean and is the Distinguished Professor in Diabetes Care/Pharmacotherapy at the Washington State University College of Pharmacy in Pullman, Washington.

R. Keith Campbell discusses his work as a pharmacist and a professor at the Washington State University and his personal experience with diabetes.

In this Exclusive Interview, Keith Campbell talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his years of experience not only as a pharmacist and diabetes educator, but as a patient with diabetes who has seen great development in a short time with more promising changes to come.